Neoadjuvant FOLFIRINOX for Pancreatic Cancer: Is the Clinical Reality Worth the Hype?

被引：0
|
作者：
Boone, B. A. [1 ]
Steve, J. [1 ]
Bahary, N. [1 ]
Zureikat, A. H. [1 ]
Zeh, H. J. [1 ]
机构：
[1] Univ Pittsburgh, Pittsburgh, PA USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2013年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [1] Neoadjuvant FOLFIRINOX in patients with resectable pancreatic cancer
    Shahda, Safi
    House, Michael G.
    Schmidt, C. Max
    Nakeeb, Attila
    Sehdev, Amikar
    Lin, Jingmei
    Cramer, Harvey M.
    Tong, Yan
    Flynn, Janet R.
    Zyromski, Nicholas J.
    O'Neil, Bert H.
    CANCER RESEARCH, 2016, 76
  • [2] Neoadjuvant FOLFIRINOX versus adjuvant gemcitabine in pancreatic cancer.
    Wolfe, Adam R.
    Miller, Eric David
    Abushahin, Laith I.
    Cloyd, Jordan
    Manilchuck, Adrei
    Dillhoff, Mary
    Pardo, Dayssy Alexandra Diaz
    Noonan, Anne M.
    Williams, Terence M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer
    Leonhardt, Carl-Stephan
    Pils, Dietmar
    Qadan, Motaz
    Gustorff, Charlotte
    Sahora, Klaus
    Klaiber, Ulla
    Warshaw, Andrew L.
    Prager, Gerald
    Ferrone, Cristina R.
    Lillemoe, Keith D.
    Schindl, Martin
    Strobel, Oliver
    Fernandez-del Castillo, Carlos
    Hank, Thomas
    EUROPEAN JOURNAL OF CANCER, 2023, 193
  • [4] Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer
    Waugh, Evelyn
    Glinka, Juan
    Breadner, Daniel
    Liu, Rachel
    Tang, Ephraim
    Allen, Laura
    Welch, Stephen
    Leslie, Ken
    Skaro, Anton
    ANNALS OF HEPATO-BILIARY-PANCREATIC SURGERY, 2024, 28 (02) : 229 - 237
  • [5] Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer
    Luu, Andreas Minh
    Hoehn, Philipp
    Vogel, SinaRabea
    Reinacher-Schick, Anke
    Munding, Johanna
    Uhl, Waldemar
    Braumann, Chris
    VISCERAL MEDICINE, 2019, 35 (06) : 387 - 390
  • [6] Clinical outcomes for modified FOLFIRINOX chemotherapy for pancreatic cancer
    Holyoake, D.
    Lo, C.
    Stubbings, H.
    Roques, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] FOLFIRINOX in pancreatic cancer
    Cidon Esther, Una
    Pilar, Alonso
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Clinical Outcomes of the Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine Versus FOLFIRINOX
    Choi, Y. J.
    Kang, J. S.
    Byun, Y.
    Kim, H. S.
    Han, Y.
    Kim, H.
    Kim, E.
    Kwon, W.
    Jang, J. Y.
    PANCREAS, 2019, 48 (10) : 1414 - 1414
  • [9] Effects of FOLFIRINOX Neoadjuvant Therapy for Pancreatic Cancer on Frozen Section Error Rates
    Crotty, Rory
    Taylor, Martin
    Deshpande, Vikram
    MODERN PATHOLOGY, 2018, 31 : 675 - 675
  • [10] Effects of FOLFIRINOX Neoadjuvant Therapy for Pancreatic Cancer on Frozen Section Error Rates
    Crotty, Rory
    Taylor, Martin
    Deshpande, Vikram
    LABORATORY INVESTIGATION, 2018, 98 : 675 - 675
12345